DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Macrophage Migration Inhibitor (MIF) Therapeutics for Neuroprotection and Prevention of Scar in Traumatic Retinal Detachment
[Technical Report, Annual Report]
OHIO STATE UNIV COLUMBUS
Pagination or Media Count:
Retinal detachment RD is a prevalent cause of blindness that is common after ocular injury to military personnel. Permanent vision loss occurs due to death of photoreceptors and formation of excessive scar tissue, known as proliferative vitreoretinopathy PVR. There are no effective pharmaceuticals to prevent these problems. The inflammatory protein, macrophage migration inhibitory factor MIF, is produced at high levels in RD and PVR, as well as in excitotoxic NMDA-mediated damage, which is important in blast injury. The proposed research will test the ability of different clinically-relevant MIF inhibitors to block photoreceptor death and abnormal healing after RD or NMDA damage in different animal models. One of these drugs, ibudilast, has already been approved for human use in Japan as an anti-inflammatory agent and is currently undergoing clinical trials in the US as a neuroprotective agent for several neurologic diseases. This research will have considerable promise for treating ocular disease triggered by military injuries. We hope it will provide ground work for a clinical trial in patients, which could one day lead to therapeutics that could prevent vision loss.
[A, Approved For Public Release]